Jeanine Harrigan
Vice President, Head of Biology TernaryTx
Jeanine Harrigan is VP, Head of Biology at Ternary Therapeutics, where she leads biology strategy and drug discovery efforts leveraging AI-enabled approaches to therapeutic development. With more than two decades of experience in discovery biology, she has held senior leadership roles at Ternary Therapeutics, Momentous Therapeutics, BenevolentAI, and Mission Therapeutics, advancing programs across multiple disease areas and modalities. Prior to industry, she conducted postdoctoral research at the University of Cambridge and the National Institute on Aging. She holds a PhD in Pharmacology and Toxicology from the University at Buffalo.
Seminars
Wednesday 27th January 2027
Panel Discussion: Can AI and Computational Methods Crack the Molecular Glue Code? Turning Predictions into Validated Hits
9:30 am
- How can AI-powered and computational approaches be used to identify gluable surfaces, target-ligase pairings, and novel molecular glue opportunities, while integrating target selection with the practical challenge of finding tractable gluable interfaces?
- How can the molecular glue field overcome limited datasets to improve model training, predictive accuracy, and biological relevance, enabling more reliable AI-driven discovery workflows?
- How can computational predictions be most effectively combined with experimental screening, structural biology, and validation strategies to accelerate hit identification and optimize molecular glue potency and selectivity?
Thursday 28th January 2027
Engineering Prospective, Rational Design of Molecular Glues
3:30 pm
- Introducing our AI models Leopard, Puffin, Gecko and Octopus
- Applying the Ternary Platform to ‘undruggable’ targets
- GRIPs: small molecule RIPTACs
